Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
09:00am, Monday, 16'th Jun 2025
Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:38am, Monday, 16'th Jun 2025
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
Sarepta Stock Crashes After Death of Second Patient Receiving Its Gene Therapy
06:18am, Monday, 16'th Jun 2025
A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug's outlook.
Sarepta shares tumble on second patient death after gene therapy treatment
05:01am, Monday, 16'th Jun 2025
Shares of Sarepta Therapeutics plunged 34% in premarket trading on Monday, a day after the company disclosed a second case of patient death due to acute liver failure after receiving its gene therapy
Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
01:57am, Monday, 16'th Jun 2025
Sarepta's stock collapsed due to ELEVIDYS safety concerns, regulatory setbacks, and reduced revenue guidance, but I see potential upside at current prices. ELEVIDYS's safety profile, especially in non
Sarepta reports second case of liver failure death after its gene therapy treatment
02:06am, Sunday, 15'th Jun 2025
Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular dyst
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
01:00am, Sunday, 15'th Jun 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrog
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?
12:36pm, Thursday, 05'th Jun 2025
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
11:06am, Thursday, 05'th Jun 2025
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the inve
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
08:30am, Wednesday, 21'st May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as E
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore
08:30am, Wednesday, 14'th May 2025
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
09:25am, Tuesday, 13'th May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, a
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
04:14am, Tuesday, 13'th May 2025
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even when
